SCHEMBL2925290

SCHEMBL2925290

COc1ccc2c(c1)C(N)=CCN2C(c1ccc(Cl)cc1)c1ccc(CN2CCOCC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.48
F10 P00742 2/20 0.40
F2 P00734 1/20 0.40
ALDH1A1 P00352 2/20 0.40
PDE4B Q07343 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PDE2A O00408 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NCOA1 Q15788 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
ACHE P22303 1/20 0.39
KCNH2 Q12809 1/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
DRD4 P21917 2/20 0.39
TSHR P16473 1/20 0.39
HIF1A Q16665 1/20 0.39
EPAS1 Q99814 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925247 0.92 PDE4B (0.45) SMN1; SMN2ALDH1A1PDE4BKDM4EPDE2A
SCHEMBL2930051 0.92 ALDH1A1 (0.42) SMN1; SMN2F10ALDH1A1KDM4EACHE
SCHEMBL2929109 0.89 SMN1; SMN2 (0.40) SMN1; SMN2F10F2ALDH1A1KDM4E
SCHEMBL2923695 0.84 CYP2A13 (0.40) SMN1; SMN2F10ALDH1A1PDE4BKDM4E
SCHEMBL4554452 0.84 DRD2 (0.40) SMN1; SMN2MEN1KMT2AKCNH2LMNA
SCHEMBL2929683 0.74 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL2926881 0.72 CYP2D6 (0.40) F10MEN1KMT2AKCNH2LMNA
SCHEMBL2925331 0.69 ALDH1A1 (0.44) ALDH1A1KDM4EKCNH2LMNA
SCHEMBL5755331 0.69 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1KDM4EKMT2ADRD4
SCHEMBL2930911 0.69 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121616-B1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2010-09-15 EP claimed
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS GIUSEPPE CAMPIANI (IT) 2010-04-15 US claimed
EP-2121616-B1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS CAMPIANI GIUSEPPE (IT) 2010-09-15 EP disclosed
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS GIUSEPPE CAMPIANI (IT) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093726-A1 NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS QTRT1, QTRT2, IL4I1 SMN1; SMN2 4673/4885F10 2911/4885F2 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.